A 62-year-old man with community-acquired pneumonia and normal renal function is started on gentamicin. Which is the most common site of aminoglycoside accumulation and toxicity?

Explanation

## Site of Aminoglycoside Accumulation and Toxicity ### Proximal Convoluted Tubule: Primary Target Organ **Key Point:** The proximal convoluted tubule (PCT) of the kidney is the most common site of aminoglycoside accumulation and toxicity. Aminoglycosides are filtered at the glomerulus and reabsorbed via endocytosis in the proximal tubular epithelium, leading to intracellular accumulation and nephrotoxicity. ### Mechanism of Renal Accumulation ```mermaid flowchart TD A[Aminoglycoside in blood]:::outcome --> B[Glomerular filtration]:::action B --> C[Filtered into tubular lumen]:::outcome C --> D[Endocytosis by proximal tubular cells]:::action D --> E[Intracellular accumulation]:::outcome E --> F{Concentration threshold exceeded?}:::decision F -->|Yes| G[Lysosomal dysfunction]:::action F -->|No| H[Exocytosis/elimination]:::action G --> I[Tubular epithelial cell necrosis]:::urgent I --> J[Acute tubular necrosis]:::outcome ``` ### Why the Proximal Tubule? 1. **High metabolic activity:** PCT cells have abundant mitochondria and active transport mechanisms 2. **Megalin-mediated endocytosis:** Aminoglycosides bind to megalin receptors on the apical membrane 3. **Lysosomal sequestration:** Drugs accumulate in lysosomes, generating reactive oxygen species (ROS) 4. **Dose-dependent toxicity:** Accumulation is saturable; once-daily dosing reduces peak intracellular concentrations ### Histopathology of Aminoglycoside Nephrotoxicity | Finding | Location | Mechanism | |---|---|---| | **Lysosomal phospholipidosis** | Proximal tubular cells | Accumulation of drug-lipid complexes | | **Mitochondrial swelling** | Proximal tubular cells | ROS-induced oxidative stress | | **Brush border loss** | Apical surface of PCT | Epithelial cell damage | | **Acute tubular necrosis** | Proximal tubule (S3 segment) | Severe cell death | | **Cast formation** | Distal tubule/collecting duct | Secondary to proximal injury | **High-Yield:** The S3 segment (straight portion) of the proximal tubule is most vulnerable because it has the highest metabolic demand and greatest aminoglycoside concentration. ### Clinical Manifestations of Proximal Tubular Injury - **Elevated serum creatinine** (marker of GFR decline) - **Elevated BUN** (urea reabsorption impaired) - **Proteinuria** (tubular dysfunction) - **Casts in urine** (tubular debris) - **Non-oliguric AKI** (most common presentation) **Clinical Pearl:** Aminoglycosides are NOT metabolized by the liver and do NOT accumulate in hepatic tissue. They are eliminated unchanged via glomerular filtration and proximal tubular reabsorption, making the kidney the primary organ at risk. ### Why NOT the Other Sites? | Site | Why Not Primary Target | |---|---| | **Cochlea** | Aminoglycosides do accumulate in the inner ear (ototoxicity), but this is less common (2–8%) than nephrotoxicity and occurs via a different mechanism (perilymph accumulation). Renal toxicity is more frequent. | | **Hepatic cells** | Aminoglycosides are not metabolized hepatically; they are water-soluble and excreted unchanged. Hepatotoxicity is not a recognized adverse effect. | | **Myocardial tissue** | Aminoglycosides do not preferentially accumulate in cardiac tissue. Cardiotoxicity is not a recognized adverse effect. | **Warning:** Do not confuse "site of accumulation" with "site of clinical manifestation." While aminoglycosides accumulate in the proximal tubule, the clinical sign (elevated creatinine) reflects overall GFR decline. Ototoxicity involves the cochlea, but nephrotoxicity is more common overall. ### Strategies to Minimize Proximal Tubular Injury 1. **Once-daily dosing:** Reduces peak intracellular concentrations 2. **Adequate hydration:** Maintains renal perfusion and reduces drug concentration in tubular fluid 3. **Dose adjustment:** Based on renal function (CrCl-based nomograms) 4. **Therapeutic drug monitoring:** Maintain trough levels <5 μg/mL for gentamicin 5. **Limit duration:** Use for 7–10 days when possible 6. **Avoid concurrent nephrotoxins:** NSAIDs, ACE inhibitors, amphotericin B